Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.
CD3-bispecifics
Checkpoint inhibitors
Combination
PKPD modeling
Journal
The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209
Informations de publication
Date de publication:
07 10 2022
07 10 2022
Historique:
received:
23
06
2022
accepted:
20
09
2022
entrez:
7
10
2022
pubmed:
8
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
TYRP1-TCB is a CD3 T-cell bispecific (CD3-TCB) antibody for the treatment of advanced melanoma. A tumor growth inhibition (TGI) model was developed using mouse xenograft data with TYRP1-TCB monotherapy or TYRP1-TCB plus anti-PD-L1 combination. The model was translated to humans to inform a refined clinical strategy. From xenograft mouse data, we estimated an EC
Identifiants
pubmed: 36207642
doi: 10.1208/s12248-022-00755-5
pii: 10.1208/s12248-022-00755-5
doi:
Substances chimiques
Antibodies, Bispecific
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Références
Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738.
doi: 10.3390/cancers12030738
pubmed: 32245016
Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):157.
doi: 10.1186/s40425-018-0479-7
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46.
doi: 10.1056/NEJMoa1910836
pubmed: 31562797
Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196–206.
doi: 10.1056/NEJMoa2103485
pubmed: 34551229
De Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GNP. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 1997;57:3223–9.
pubmed: 9242453
de Vries TJ, Trancilkova D, Ruiter DJ, van Muijen GNP. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer. 1998;78(9):1156–61.
doi: 10.1038/bjc.1998.646
pubmed: 9820172
pmcid: 2063001
Nicolini VG, Waldhauer I, Freimoser-Grundschober A, Richard M, Fahrni L, Bommer E, et al. Abstract LB-389: combination of TYRP1-TCB, a novel T cell bispecific antibody for the treatment of melanoma, with immunomodulatory agents. Cancer Res. 2020;80(16 Supplement):LB-389.
doi: 10.1158/1538-7445.AM2020-LB-389
Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941–4.
doi: 10.1158/0008-5472.CAN-09-0547
pubmed: 19509221
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24(19):4785–97.
doi: 10.1158/1078-0432.CCR-18-0455
pubmed: 29716920
Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22(13):3286–97.
doi: 10.1158/1078-0432.CCR-15-1696
pubmed: 26861458
Mathur D, Root AR, Bugaj-Gaweda B, Bisulco S, Tan X, Fang W, et al. A novel GUCY2C-CD3 T-cell engaging bispecific construct (PF-07062119) for the treatment of gastrointestinal cancers. Clin Cancer Res. 2020;26(9):2188–202.
doi: 10.1158/1078-0432.CCR-19-3275
pubmed: 31996389
Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 2014;74(19):5561–71.
doi: 10.1158/0008-5472.CAN-13-3622-T
pubmed: 25228655
Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021;2(4):354–69.
doi: 10.1158/2643-3230.BCD-21-0038
pubmed: 34258584
pmcid: 8266040
Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, et al. Combination of T-cell bispecific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity. Front Oncol. 2020;10: 575737.
doi: 10.3389/fonc.2020.575737
pubmed: 33330050
pmcid: 7735156
Wunderlich M, Manning N, Sexton C, O’Brien E, Byerly L, Stillwell C, et al. PD-1 inhibition enhances blinatumomab response in a UCB/PDX model of relapsed pediatric B-cell acute lymphoblastic leukemia. Front Oncol. 2021;11: 642466.
doi: 10.3389/fonc.2021.642466
pubmed: 33928030
pmcid: 8076590
Osada T, Patel SP, Hammond SA, Osada K, Morse MA, Lyerly HK. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother. 2015;64(6):677–88.
doi: 10.1007/s00262-015-1671-y
pubmed: 25742933
Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, et al. Tumor-targeted 4–1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. 2019;11(496):eaav5989.
doi: 10.1126/scitranslmed.aav5989
pubmed: 31189721
pmcid: 7181714
Chiu D, Tavare R, Haber L, Aina OH, Vazzana K, Ram P, et al. A PSMA-targeting CD3 bispecific antibody induces antitumor responses that are enhanced by 4–1BB costimulation. Cancer Immunol Res. 2020;8(5):596–608.
doi: 10.1158/2326-6066.CIR-19-0518
pubmed: 32184296
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(20):3239–47.
doi: 10.1200/JCO.2008.21.6457
pubmed: 20498403
Xu J, Higgins MJ, Tolaney SM, Come SE, Smith MR, Fornier M, et al. A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases. Oncologist. 2020;25(8):652–60.
doi: 10.1634/theoncologist.2020-0127
pubmed: 32463152
pmcid: 7418363
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.
doi: 10.1056/NEJMoa1602252
pubmed: 27718784
pmcid: 5564292
Backes FJ, Wei L, Chen M, Hill K, Dzwigalski K, Poi M, et al. Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. Gynecol Oncol. 2021;162(3):619–25.
doi: 10.1016/j.ygyno.2021.06.032
pubmed: 34272090
Pearson T, Greiner DL, Shultz LD. Creation of “humanized″ mice to study human immunity. Curr Protoc Immunol. 2008;Chapter 15:Unit 15 21.
Monolix version 2019R2. 2019R2 ed. Antony, France: Lixoft SAS, 2019: Lixoft; 2019.
Krippendorff BF, Kuester K, Kloft C, Huisinga W. Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn. 2009;36(3):239–60.
doi: 10.1007/s10928-009-9120-1
pubmed: 19554432
pmcid: 2718226
Fronton L, Pilari S, Huisinga W. Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models. J Pharmacokinet Pharmacodyn. 2014;41(2):87–107.
doi: 10.1007/s10928-014-9349-1
pubmed: 24493102
Betts A, Keunecke A, van Steeg TJ, van der Graaf PH, Avery LB, Jones H, et al. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. MAbs. 2018;10(5):751–64.
doi: 10.1080/19420862.2018.1462429
pubmed: 29634430
pmcid: 6150614
Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol. 2009;27(25):4103–8.
doi: 10.1200/JCO.2008.21.0807
pubmed: 19636014
Chatterjee MS, Elassaiss-Schaap J, Lindauer A, Turner DC, Sostelly A, Freshwater T, et al. Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma. CPT Pharmacomet Syst Pharmacol. 2017;6(1):29–39.
doi: 10.1002/psp4.12140
Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci. 1986;75(11):1028–40.
doi: 10.1002/jps.2600751104
pubmed: 3820096
Lindauer A, Valiathan CR, Mehta K, Sriram V, de Greef R, Elassaiss-Schaap J, et al. Translational pharmacokinetic/pharmacodynamic modeling of tumor growth inhibition supports dose-range selection of the anti-PD-1 antibody pembrolizumab. CPT Pharmacomet Syst Pharmacol. 2017;6(1):11–20.
doi: 10.1002/psp4.12130
Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2019.
Fidler M, Hallow M, Wilkins J, Wang W. RxODE: facilities for simulating from ODE-based models. 2021.
Eigenmann MJ, Karlsen TV, Wagner M, Tenstad O, Weinzierl T, Fauti T, et al. Pharmacokinetics and pharmacodynamics of T-cell bispecifics in the tumour interstitial fluid. Pharmaceutics. 2021;13(12):2105.
doi: 10.3390/pharmaceutics13122105
pubmed: 34959386
pmcid: 8705663
Fabian KP, Padget MR, Fujii R, Schlom J, Hodge JW. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. J Immunother Cancer. 2021;9(2):e001691.
doi: 10.1136/jitc-2020-001691
pubmed: 33602696
pmcid: 7896589
Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, et al. Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy. Drug Des Devel Ther. 2020;14:3625–49.
doi: 10.2147/DDDT.S267433
pubmed: 32982171
pmcid: 7490077
Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, clinicalguidelines@esmo.org EGCEa. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(12):1884–901.
doi: 10.1093/annonc/mdz411
pubmed: 31566661
Tabernero J, Melero I, Ros W, Argiles G, Marabelle A, Rodriguez-Ruiz ME, et al. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2017;35(15_suppl):3002.
doi: 10.1200/JCO.2017.35.15_suppl.3002
Shah M, Rahman A, Theoret MR, Pazdur R. The drug-dosing conundrum in oncology: when less is more. N Engl J Med. 2021;385(16):1443–5.
doi: 10.1056/NEJMp2109826